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Background: Extraskeletal myxoid chondrosarcoma (EMCS) is a rare soft tissue sarcoma of uncertain differentiation,
characterized in most cases by a translocation that results in the fusion protein EWSR1-CHN (the latter even called
NR4A3 or TEC). EMCS is marked by >40% incidence of metastases in spite of its indolent behaviour. It is generally
resistant to conventional chemotherapy, and, to the best of our knowledge, no data have been reported to date
about the activity of tirosin-kinase inhibitor (TKI) in this tumor. We report on two consecutive patients carrying an
advanced EMCS treated with sunitinib.
Methods: Since July 2011, 2 patients with progressive pretreated metastatic EMCS (Patient1: woman, 58 years, PS1;
Patient2: man, 63 years, PS1) have been treated with continuous SM 37.5 mg/day, on an individual use basis. Both
patients are evaluable for response. In both cases diagnosis was confirmed by the presence of the typical EWSR1-
CHN translocation.
Results: Both patients are still on treatment (11 and 8 months). Patient 1 got a RECIST response after 4 months from
starting sunitinib, together with a complete response by PET. An interval progression was observed after stopping
sunitinib for toxicity (abscess around previous femoral fixation), but response was restored after restarting sunitinib.
Patient 2 had an initial tumor disease stabilization detected by CT scan at 3 months. Sunitinib was increased to
50 mg/day, with evidence of a dimensional response 3 months later.
Conclusions: Sunitinib showed antitumor activity in 2 patients with advanced EMCS. Further studies are needed to
confirm these preliminary results.
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Extraskeletal myxoid chondrosarcoma (EMCS) is a rare
soft-tissue sarcoma (STS) first described in 1972 [1,2].
EMCS is now considered a unique entity of uncertain dif-
ferentiation (convincing evidence of a cartilaginous differ-
entiation is lacking in most cases) [3]. Besides, EMCS can
have a neuroendocrine differentiation [4-6].
It is market by a specific chromosomal translocation,
t(9;22)(q22.3;q12.2), fusing CHN to EWSR1 [7,8]. Less
frequently two different translocations, t(9;17)(q22.3;q12)
and t(9;15)(q22.3;q21.3) are found, resulting in RBP56-
CHN and TCF12-CHN fusion-genes, respectively [9,10].* Correspondence: silvia.stacchiotti@istitutotumori.mi.it
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distribution, and reproduction in any mediumThe fusion-proteins promote cellular growth and differen-
tiation [11]. Furthermore, the EWSR1-CHN fusion-protein
may activate the PPARG nuclear receptor gene [12].
Microscopically, EMCS can be subdivided into a conven-
tional well-differentiated and a cellular high-grade
EMCS, which is marked by epithelioid cells with promin-
ent nucleoli, high mitotic rate and necrosis [13]. Dediffer-
entiated ECMS were also described [14].
Most EMCS arise from the deep soft tissues of the
extremities and limb girdles [15-20]. The natural history
is usually characterized by an indolent behavior, but stud-
ies with a long median follow-up show a high-rate of late
local and distant tumor recurrence despite a prolonged
clinical course [16-21]. Metastases are reported in around
40% of cases, with a 58% overall survival rate at 15 years
in the largest retrospective series [20].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gical resection, followed by radiation in high-risk cases
[21]. Patients with advanced disease usually receive a
medical treatment. Unfortunately, response rates to con-
ventional chemotherapy are low [15,21-24].
Case report
A 53-year female patient was diagnosed with a 20-cm
mass located to the right thigh in October 2006. Con-
comitant ipsilateral iliac lymph nodes (LN) were present.
Both sites were biopsied, with a pathologic diagnosis
of EMCS (Figure 1). In both samples histology showed a
diffuse pancytokeratin (AE1/AE3) cytoplasmic staining
and PPARG nuclear expression, whileS-100 protein, smooth
muscle actin, synaptophysin and brachyury were nega-
tive. EWSR1 and CHN gene status was investigated by
dual-color break-apart FISH which detected a balanced
rearrangement for both genes. Figure 1D shows the FISH
rearranged pattern for CHN.
The identification of a CHN translocation partner
ruled-out the diagnosis of myoepithelial carcinoma,
raised by morphology and cytokeratin immunoreactivity,
as well as an ossifying fibromixoid tumor, another ECMS
mimic [25]. Indeed, a subset of soft tissue myoepithelial
carcinomas were recently reported to harbour EWSR1-
POU5F1 chimera [26] widening the growing family ofA
C
Figure 1 Patient 1 tumor biopsy consistent with the diagnosis of extr
epithelioid cells embedded into a myxoid matrix (HandE) (panel A), charac
(panel B) and PPARG nuclear expression (panel C). Panel D shows the FISH
corresponding to an intact copy of the gene, and a split signal (red and grEWSR1 gene-rearranged tumors and thus making the
EWSR1 rearrangement test alone unable to discriminate.
The patient was treated with anthracycline-based
chemotherapy. This was followed by a wide excision of
the primary tumor en-bloc with a partial femur resection
plus ipsilateral iliac LN dissection, and adjuvant radio-
therapy on the tumor bed and on the right iliac region. A
first multifocal intrabdominal/retroperitoneal relapse was
detected in February 2008, and was treated with high-dose
ifosfamide plus complete surgical resection. In December
2009, lung metastases appeared. A third-line chemother-
apy with trabectedin was started, with progression. Lack-
ing any conventional alternative, in June 2011 the patient
started sunitinib 37.5 mg/day, on a continuous dosing
regimen. Treatment was provided within a compassionate
use program, with the approval of the Institutional Ethics
Committee. At that time the disease involved the lungs,
liver, abdomen, soft tissues, as confirmed by computed
tomography scan (CT) and [18F]fluorodeoxyglucose–
positron emission tomography scan (PET). No evidence of
relapse to the primary tumor site was observed. Patient
was asymptomatic, ECOG performance status (PS) = 1.
A complete response by PET to all lesions was evident
after 4 weeks of treatment (Figure 2B) with a marked de-
crease in maximum SUV, along with a decrease in tumor
size and contrast uptake on CT (Figure 3B).B
D
askeletal myxoid chondrosarcoma. Histology shows nests/cords of
terized by diffuse pancytokeratin (AE1/AE3) cytoplasmic decoration
rearranged pattern for CHN, consisting in a fusion green/red signal,
een separated, white arrows) corresponding to the rearranged allele.




Figure 2 [18F]fluorodeoxyglucose–positron emission tomography scan (PET) tumor assessment. In panels A and B (white arrows) PET
shows a marked decrease in maximum SUV comparing the tumor before and after 4 weeks of treatment. Panel C shows an interval tumor
progression at 6 months from baseline, i.e. after 2 months from sunitinib interruption and treatment with antibiotics.
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apy was complicated by an abscess to the primary site,
around femoral fixation. The infection was confirmed by
clinical signs (fever, leukocytosis, redness, calor and pain
located to the thigh), CT and PET. In fact, CT showed a
tumor response to all sites, as described above, together
with a new mass in the right gluteus muscles character-
ized by fluid content with rim enhancement (Figure 4C)
which was not evident at baseline (Figure 4A). It was
located below the painful right tight skin area. Consist-
ently, that area became positive on PET (Figure 4D).
Sunitinib was thus interrupted after 5 weeks and anti-
biotics were started, with progressive resolution of the
infection, as confirmed by CT and PET three months
later (Figure 4F). At that time, CT confirmed the tumor
response to sunitinib with evidence of >30% shrinkage,
thus consistent with a RECIST response (Figure 3C). Thepatient was not on treatment anymore, due to the com-
plicated tumor response. A new progression was observed
5 months after treatment interruption (6 months from
baseline), as shown by PET and CT in Figure 2C
and Figure 3D. Thus sunitinib 37.5 mg/day was
re-established, achieving a new CT response one month
later (Figure 3E).
Following this experience another 67-years old con-
secutive patients, ECOG PS 1, affected by a EWSR1-CHN
translocated progressive EMCS, metastatic to the lung
and LN, pretreated with multiple lines of chemotherapy,
started sunitinib in October 2011. After 3 months of
treatment with sunitinib 37.5 mg/day a tumor disease
stabilization was observed. At that point sunitinib was
tentatively increased to 50 g/day, with a dimensional re-
sponse by CT detectable after 3 months of therapy, 6
months from baseline.
baseline + 4 mos+ 1 mos
+ 6 mos + 7 mos
A B C
D E
Figure 3 Computed Tomography scan (CT) tumor assessment. In panels A, B, C (white arrows) CT, venous phase, after contrast medium,
shows a peritoneal metastasis at baseline, after 1 and 4 months of sunitinib with evidence of 30% decrease in tumor size and contrast uptake.
Panel D shows an interval tumor progression at 6 months from baseline, i.e. after 2 months from sunitinib interruption, while panel E shows a
new response at 7 months, 4 weeks after restoring sunitinib.
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and 8 months from baseline, respectively, without evi-
dence of further major side effects.
Discussion
We report on the tumor response to sunitinib in two
consecutive patients with pretreated, progressive, meta-
static extraskeletal myxoid chondrosarcoma, carrying the
EWSR1-CHN translocation. In the first case the response
was evident after only one month of treatment and
marked by shrinkage of all lesions, on the face of a
complete PET response. Decrease in tumor size was con-
firmed by further CT scans for 4 months after stopping
treatment because of a therapy-related abscess. When
disease progressed after 4 months from sunitinib discon-
tinuation, response was restored by restarting treatment.
At 9+ months of follow-up, tumor response was con-
firmed. In the second patient a dimensional response was
evident at 6 months, after an initial tumor stabilization.
EMCS is a very rare STS, with low sensitivity to
cytotoxic chemotherapy [15,20-24]. The only responses
to chemotherapy were reported by McGrory in 2 of 6
metastatic EMCS patients responsive to a multi-agents
chemotherapy [21], and in one patient treated withanthracycline plus ifosfamide described by Han [24]. No
objective responses were observed in the MD Andersen
series [23] of 10 patients receiving doxorubicin and
dacarbazine-based regimens, nor in the series of 21 patients
treated with different regimens, mostly anthracycline-based,
reported by Memorial Sloan Kettering and Royal Marsden
[20]. Finally, a response to interferon-α-2b was also
described [27]. To our knowledge, this is the first report
on the activity of an antiangiogenic agent in EMCS.
Sunitinib is a multi-targeted tyrosine-kinase (RTK) in-
hibitor and antiangiogenic drug approved for the treat-
ment of gastrointestinal stromal tumor (GIST) and renal
cancer [28,29]. Evidence of activity in selected STS
subtypes other than GIST has been provided [30-34].
Responses are often non dimensional, with some excep-
tion as for alveolar soft part sarcoma (ASPS) [30]. Of
interest, in these patients with ESMC we could observe a
major dimensional response.
Unlike GIST, no specific genetic alterations associated
with sensitivity to sunitinib have been identified in STS.
As shown in ASPS [30], another STS bearing a trans-
location, the antitumor activity of sunitinib is unlikely to
be directly linked to the fusion-protein. In the absence










Figure 4 Computed Tomography scan (CT) and [18F]fluorodeoxyglucose–positron emission tomography scan (PET) abscess evaluation.
CT showed a new mass in the right gluteus muscles characterized by fluid content with rim enhancement (panel C) which was not evident at
baseline (panel A). That area became positive on PET (panel D) compared to baseline (panel B). CT (panel E) and PET (panel F) confirmed the
resolution of the infection, three months later after sunitinib interruption and treatment with antibiotics.
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the autocrine-paracrine PDGFR/VEGFR activation-loop
have been advocated as possible explanations for its
antitumor activity [30]. Even in EMCS the fusion-protein
is unlikely to be related to sunitinib sensitivity [12].
Unfortunately, due to absence of untreated frozen mater-
ial, we could not assess the RTK activation profile.
The most common toxicities with sunitinib are hand-
foot syndrome, rash, fatigue, hypertension, hypothyroid-
ism and diarrhea. It is known that the sunitinib and other
antiangiogenetic agents can interfere also with the nor-
mal vasculature formation and, possibly, with the T-cell
mediated immunity [28,35,36]. This can lead to rare
complications, such as abscess formation [37-39]. In our
first patient, the abscess originated at a site where there
was no evidence of disease and was probably related to
the presence of the foreign material for the femoral fix-
ation. For the differential diagnosis, CT is viewed as the
most accurate exam. In our case the presence of clearclinical signs of infection, as fever, leukocytosis, calor and
redness of the skin, were of much help to rule out an iso-
lated disease progression. A conservative approach was
enough to heal the abscess and a drainage could be
avoided. However, CT findings may sometimes be insuffi-
cient for the diagnosis and a biopsy can be necessary to
rule out a disease progression.Conclusion
A tumor response to sunitinib was seen in two consecu-
tive patients with EMCS. In one case the response was
complicated by infection and was restored when treatment
could be restarted after a while. Differential diagnosis of
complicated tumor response versus tumor progression
was crucial to continue with therapy in the first respond-
ing patient. Further prospective studies are needed to con-
firm these results and to better understand the molecular
basis for the activity of sunitinib in this disease.
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